top of page

HOME
COMPANY
NEWS
TECHNOLOGY
- R&D
- QUALITY
SERVICES
CONTACT
More

Use tab to navigate through the menu items.

Characterization of a novel LQT3 variant with a selective efficacy of mexiletine treatment.

Characterization of a novel LQT3 variant with a selective efficacy of mexiletine treatment.

GC Genome Corporation I Representative: KI CHANG SEOK I Business Registration No. 142-81-61687

107, Ihyeon-ro 30beon-gil, Giheung-gu, Yongin-si, Gyeonggi-do, 16924, Korea

Email. info@gcgenome.com I Tel. +82 31-280-9939 I Fax. +82 31-260-9087

©2021 by GC Genome.

bottom of page